PREVENT BREAST (CPMS  72067, IRAS 363469)

UPDATED - 14/08/2026

STUDY SUMMARY

The PREVENT-Breast study is a parallel-group randomised controlled trial designed to evaluate and compare the uptake of proactive multifactorial breast cancer risk assessment (using the CanRisk tool) in primary care amongst South Asian and Black women aged 40–49. 

While identifying high-risk women under 50 for enhanced screening and preventive medication is highly effective, routine pathways relying on self-presentation often fail to reach those from ethnic minority backgrounds. Building upon previous feasibility research, this study compares a "non-adapted" (control) pathway with an "adapted" (intervention) pathway. The adapted pathway has been co-designed with women from the target communities to include tailored, multilingual invitation materials, audio-visual resources, and direct 1-to-1 language and navigation assistance.

By participating in this study, general practices will help address critical health inequalities and explore cost-effective, scalable ways to proactively manage breast cancer risk. GP practices will be selected from areas with higher populations of Black and South Asian women across Cambridgeshire, Peterborough, and Manchester. Participating practices in Cambridgeshire and Peterborough will focus on recruiting Black women and must refer all family history cases to the Cambridge University Hospital NHS Foundation Trust, while those in Manchester will focus on recruiting South Asian women.

INCLUSION CRITERIA:

• Female sex as defined at birth.

• Aged 40-49 years at the time of invitation.

• Registered with a participating general practice that refers patients to Cambridge University Hospitals NHS Foundation Trust.

• Identified in their medical records as of Black ethnic background.

EXCLUSION CRITERIA:

• Have an entry in their medical records showing a personal history of breast or ovarian cancer.

• Have an entry in their medical records showing a previous diagnosis of metastatic cancer or entry on the palliative care register.

• Have an entry in their medical records showing they have given prior notification of dissent to research.

• Self-report that they have previously been tested for a high-risk mutation for breast cancer.

• Self-report that they have already participated in the CanRisk-GP or BCAN-RAY studies.

• Self-report that they have undergone or are undergoing hormonal treatment for gender reassignment.

Study Resources

Access for the SystmOne and EMIS study resources can be requested below.

For further guidance on using the resources, please refer to the guidance documents and further useful information on the PRIDES page.

The searches have been created with the study specific inclusion and exclusion criteria. 

If you require any further information or help, please contact the IT Specialists:

EMIS: Jodie Button – jodie.button@nihr.ac.uk 

SystmOne:  Sharon Harper - sharon.harper2@nhs.net

Disclaimer:

Please note the resources provided are designed to assist with the identification of potentially suitable patients and to appropriately code these patients if required.

These resources have been developed based on the criteria provided by the relevant study team and whilst every effort has been made to make them universally implementable they rely on read codes and the data stored in the individual practice's clinical system. These resources are intended to assist with identification but should be used in conjunction with clinical oversight and a clear understanding of the study parameters.

While we endeavour to keep the information, tools and resources provided up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the tools provided for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of the tools provided.